The purpose of this study is to evaluate if the drug GTX-102 is effective with the Angelman population. This is a Phase 3 study, that is a double-blind, sham-controlled study.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Elizabeth Jalazo
Carolina Institute for Developmental Disabilities
Clinical or Medical
Interventional
Genetics and Genetic Disorders
24-2478
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
